Calcipotriol

Generic Name: Calcipotriol

Brand Names: Calcitrene, Dovobet, Dovonex, Enstilar, Sorilux, Taclonex, Wynzora

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₀O_₃

CAS Number: 112965-21-6

Unique Ingredient Identifier: 143NQ3779B

Background: Calcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.

Indication: For the treatment of moderate plaque psoriasis in adults.

Associated Conditions: Plaque psoriasis of the scalp, Psoriasis Vulgaris (Plaque Psoriasis)

Clinical Trials

Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

Phase 2

Completed

Conditions: Pruritus
Psoriasis

Interventions: Drug: SNA-120
Drug: Placebo
Drug: Calcipotriene

First Posted Date: 2018-02-27

Last Posted Date: 2019-02-08

Lead Sponsor: Sienna Biopharmaceuticals

Target Recruit Count: 73

Registration Number: NCT03448081

Locations: 🇺🇸
Site 015, Sanford, Florida, United States
🇺🇸
Site 013, Coral Gables, Florida, United States
🇨🇦
Sienna 003, Montreal, Quebec, Canada

and more 17 locations

Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis

Phase 4

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Vehicle
Drug: Enstilar
Drug: Otezla

First Posted Date: 2018-02-22

Last Posted Date: 2019-03-14

Lead Sponsor: L.H. Kircik, M.D.

Target Recruit Count: 28

Registration Number: NCT03441789

Locations: 🇺🇸
Center for Dermatology and Laser Surgery, Sacramento, California, United States
🇺🇸
Skin Sciences, PLLC, Louisville, Kentucky, United States
🇺🇸
Dermatology & Laser Center of Charleston, Charleston, South Carolina, United States

and more 1 locations

1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: Clobetasol 0.05% ointment
Drug: Mapracorat (ZK 245186, BAY 86-5319)
Drug: Calcipotriene 0.005% ointment
Drug: Prednicarbate 0.25% ointment
Drug: Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment

First Posted Date: 2018-01-16

Last Posted Date: 2018-01-16

Lead Sponsor: Bayer

Target Recruit Count: 24

Registration Number: NCT03399526

Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis

Phase 1

Completed

Conditions: Psoriasis
Mesenchymal Stromal Cells
Drug Effect
Drug Toxicity

Interventions: Drug: Calcipotriol ointment
Biological: adipose-derived multipotent mesenchymal stem cells

First Posted Date: 2018-01-05

Last Posted Date: 2023-08-24

Lead Sponsor: Guangdong Provincial Hospital of Traditional Chinese Medicine

Target Recruit Count: 8

Registration Number: NCT03392311

Locations: 🇨🇳
Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China

To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis

Phase 3

Completed

Conditions: Scalp Psoriasis

Interventions: Drug: Calcipotriene/Betamethasone Dipropionate
Drug: Placebo
Drug: Taclonex®

First Posted Date: 2017-11-06

Last Posted Date: 2018-12-21

Lead Sponsor: Glenmark Pharmaceuticals Ltd. India

Target Recruit Count: 643

Registration Number: NCT03331523

Locations: 🇺🇸
Investigational Site 25, Las Vegas, Nevada, United States
🇺🇸
Investigational Site 18, Fountain Inn, South Carolina, United States
🇺🇸
Investigational Site 8, Nashville, Tennessee, United States

and more 28 locations

The Effect of Fractional Co2 Laser Either With Tacrolimus, Calcipotriol or NB-UVB in Stable Generalized Vitiligo

Phase 1

Conditions: Vitiligo Vulgaris

Interventions: Drug: Tacrolimus ointment
Drug: calcipotriol ointment
Drug: NB-UVB

First Posted Date: 2017-07-31

Last Posted Date: 2017-08-01

Lead Sponsor: Assiut University

Target Recruit Count: 30

Registration Number: NCT03234673

BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis

Phase 1

Completed

Conditions: Scalp Psoriasis

Interventions: Drug: Placebo
Drug: Calcipotriene and betamethasone suspension
Drug: Taclonex

First Posted Date: 2017-04-20

Last Posted Date: 2018-03-07

Lead Sponsor: Tolmar Inc.

Target Recruit Count: 699

Registration Number: NCT03122353

Locations: 🇺🇸
Site 29, Fremont, California, United States
🇺🇸
Site 18, Sherman Oaks, California, United States
🇺🇸
Site 01, Brandon, Florida, United States

and more 31 locations

Enstilar in Combination With Biologic Agents

Phase 4

Completed

Conditions: Psoriasis

Interventions: Drug: Enstilar 0.005%-0.064% Topical Foam

First Posted Date: 2017-03-15

Last Posted Date: 2018-01-03

Lead Sponsor: Psoriasis Treatment Center of Central New Jersey

Target Recruit Count: 25

Registration Number: NCT03080545

Locations: 🇺🇸
Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States

Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis

Phase 1

Completed

Conditions: Psoriasis Vulgaris
Psoriasis

Interventions: Drug: HAT1 topical solution
Drug: Calcipotriol

First Posted Date: 2017-03-03

Last Posted Date: 2017-03-03

Lead Sponsor: Haus Bioceuticals

Target Recruit Count: 28

Registration Number: NCT03069144

Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test

Phase 1

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: SOR007 Ointment 2.0%
Drug: SOR007 Ointment 1.0%
Drug: SOR007 Ointment 0.3%
Drug: SOR007 Ointment 0.15%
Drug: SOR007 Ointment Placebo
Drug: Taclonex® Ointment

First Posted Date: 2016-12-28

Last Posted Date: 2019-02-15

Lead Sponsor: DFB Soria, LLC

Target Recruit Count: 13

Registration Number: NCT03004339

Locations: 🇺🇸
DermResearch, Inc., Austin, Texas, United States
🇺🇸
J&S Studies, Inc., College Station, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy